...
首页> 外文期刊>Infectious Diseases and Therapy >Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study
【24h】

Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study

机译:早期,低剂量,短期皮质类固醇治疗非严重柯伊德-19肺炎的疗效评估:回顾性队列研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

ObjectivesThis study aimed to observe the efficacy of corticosteroids in non-severe COVID-19 pneumonia.MethodsA retrospective study based on propensity score matching was designed to explore the effects of corticosteroids. Primary outcomes included the rate of patients who developed severe disease and mortality. Secondary outcomes included duration of fever, virus clearance time, length of hospital stay, and the use of antibiotics.ResultsA total of 475 patients with non-severe COVID-19 pneumonia were enrolled, 55 patients received early, low-dose, and short-term corticosteroids therapy, 420 patients received non-corticosteroids therapy. Compared to the non-corticosteroids group, there was a prolonged duration of fever (median 5 vs 3?days, p ?0.001), virus clearance time (median 18 vs 11?days, p ?0.001), and length of hospital stay (median 23 vs 15?days, p ?0.001) in the corticosteroids group. The percentages of antibiotics therapy (89.1% vs 23.6%, p ?0.001), use of at least two antibiotics?(38.2% vs 12.7%, p =?0.002), and antifungal therapy (7.3% vs 0, p =?0.042) were higher in the corticosteroids group than those in the non-corticosteroids group. Compared to the non-corticosteroids group, more patients developed severe disease (12.7% vs 1.8%, p =?0.028) in the corticosteroids group. There was no?significant?difference between the two groups in mortality (1.8% vs 0, p =?0.315).ConclusionIn adult patients with non-severe COVID-19 pneumonia, early, low-dose, and short-term corticosteroids therapy was associated with worse clinical outcomes.
机译:客观的研究旨在观察皮质类固醇在非严重Covid-19肺炎中的疗效。基于倾向评分匹配的方法,旨在探讨皮质类固醇的影响。主要结果包括发展严重疾病和死亡率的患者的速率。二次结果包括发烧持续时间,病毒间隙时间,住院时间长度,以及使用抗生素。患有475例非严重Covid-19肺炎的患者,55名患者接受早期,低剂量,短暂 - 术语皮质类固醇治疗,420名患者接受非皮质类固醇治疗。与非皮质类固醇组相比,延长了持续时间的发烧(中位5 vs 3?天,P <0.001),病毒间隙时间(中位数18 vs 11?天,P <0.001),以及医院的长度在皮质类固醇组中保持(中位数23 vs 15?天,p <0.001)。抗生素治疗的百分比(89.1%vs 23.6%,p <0.001),使用至少两种抗生素?(38.2%vs 12.7%,p = 0.002)和抗真菌治疗(7.3%Vs 0,p =?皮质类固醇组在0.042)比非皮质类固醇组中的较高。与非皮质类固醇组相比,更多患者在皮质类固醇组中发育严重的疾病(12.7%vs 1.8%,p = 0.028)。没有?显着的?两组死亡率之间的差异(1.8%Vs 0,p = 0.315)。成年患者的非严重Covid-19肺炎,早期,低剂量和短期皮质类固醇治疗与更糟糕的临床结果相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号